ANCA Vlad Net Worth 2026: Estimate, Sources, and Breakdown

Anca Vlad is a Romanian businesswoman and the founder and president of the Fildas-Catena Group, Romania's largest pharmaceutical distribution and pharmacy retail network. Our best current estimate of her net worth sits in the range of €600 to €700 million, with a single working figure of approximately €650 million as of mid-2026. That range is anchored by Capital Romania's Top 300 wealthiest Romanians list, which pegged her fortune at €660-700 million in its most recent reporting, and is corroborated by the financial scale of her operating businesses.

Who exactly is Anca Vlad? Clearing up the identity

The name 'Anca Vlad' is not uniquely associated with one person, so it is worth confirming who we are tracking here. The person this article covers is the Romanian businesswoman born in the mid-1960s who built Fildas Trading and the Catena pharmacy chain from the ground up. She is consistently identified in Forbes Romania, Capital Romania, and Ziarul Financiar as the controlling owner of the Fildas-Catena Group, and her official site (ancavlad.ro) presents the same biographical details.

The potential for confusion is real. A separate individual named Anca Vlad appears in North American corporate directories linked to Concentra Bank in Toronto, and the name is common enough in Romanian-speaking regions to produce multiple search results across industries. There is no verified connection between the Toronto-linked individual and the pharma entrepreneur. Throughout this article, 'Anca Vlad' refers exclusively to the president of Fildas-Catena, the figure relevant to an Eastern European wealth tracker. Because the name can be confused in search results, anyone looking up “Vladik Oladik” should treat any net worth figures as belonging to a different person until verified. The 'Vlad' surname also surfaces in searches for other regional figures, and readers searching more broadly may encounter profiles for people like Vlad Plahotniuc or Vladik Oladik, who are entirely separate individuals with their own distinct wealth profiles. Some readers may also be searching for Vlad Plahotniuc net worth, which refers to a different individual and a separate wealth profile.

Current net worth estimate: the range and the best single figure

Based on aggregated reporting and business financial data available through early 2026, the most defensible net worth range for Anca Vlad is €600 million to €700 million. The midpoint of that range, roughly €650 million, is the figure we use as the working estimate. If you are comparing figures like vlad nikita net worth across similar business profiles, treat this working midpoint as the closest single-number snapshot until a newer wealth listing or filing-based update appears.

The trajectory alone tells a compelling story. Her tracked fortune roughly tripled from the €270-300 million range in 2017 to the €660-700 million range in recent years, driven almost entirely by the growth of Fildas and Catena during a period of rapid pharmaceutical retail consolidation in Romania. The older €84 million figure from around 2013-2015 represents an earlier phase before the group crossed €1 billion in annual turnover.

Where the money comes from

Anca Vlad's wealth is almost entirely enterprise-driven rather than diversified across public markets or real estate speculation. Her core income streams flow from two tightly linked pillars: pharmaceutical distribution through Fildas Trading and pharmacy retail through the Catena chain.

Fildas Trading: the distribution engine

Fildas Trading is the group's wholesale pharmaceutical distributor. According to figures published on the official Fildas site and corroborated by Ziarul Financiar, the company posted turnover of RON 4.2 billion (roughly €860 million at the time) back in 2019, representing 16% year-on-year growth. By 2023, the group's reported turnover had crossed €1.3 billion, and its market share stood at approximately 22% of Romania's pharmaceutical distribution market. Anca Vlad owns 100% of Fildas Trading's capital, meaning all distributable profits flow directly to her.

Catena pharmacies: the retail network

Catena is one of Romania's largest pharmacy chains by outlet count, operating hundreds of locations nationwide. The pharmacy retail arm generates revenue independently from the distribution side and adds a layer of consumer-facing brand value that makes the group more resilient than a pure wholesaler. Anca Vlad's ownership position in the Catena structure is evidenced by corporate legal documents showing her involvement in share issuances involving Catena Pharma and affiliated entities like Farmavit Plus SRL.

Smart Soft Power: the technology subsidiary

Ziarul Financiar reported, citing data from Romania's Ministry of Public Finance, that Smart Soft Power (an IT services company) is controlled by Anca Vlad and recorded a net profit of 12.9 million lei in 2025, up from 8.9 million lei the prior year. The company's main customers are Catena and Fildas Trading, making it effectively an in-house technology arm of the group. It contributes a modest but growing profit stream and represents an in-kind digital infrastructure investment that reduces costs across the broader group.

Assets and holdings

The Fildas-Catena Group's physical infrastructure is itself a significant asset base. The group operates a national warehouse and logistics network supporting pharmaceutical distribution to hospitals and pharmacies across Romania. Combined with the pharmacy retail locations, these represent substantial fixed assets that contribute to the group's balance sheet and, by extension, to Anca Vlad's net worth as the controlling owner.

Beyond the core group, corporate registry filings and legal documents confirm her involvement in a broader holding structure that includes multiple legal entities. Farmavit Plus SRL is one example where her name appears directly in share issuance documentation alongside Fildas Trading, suggesting a layered ownership arrangement typical of Romanian family-owned business groups of this scale.

Public records do not prominently surface large-scale personal real estate holdings or significant public equity portfolios for Anca Vlad. Her wealth profile is fundamentally that of a closely held operating business owner rather than a portfolio investor, which is common among Eastern European entrepreneurs who built companies organically during the post-communist privatization era.

How we built this estimate: verified data vs assumptions

Transparency about methodology matters here because Romania does not require individuals to publicly disclose personal net worth, and there are no mandatory wealth declarations for private business owners (unlike politicians). Here is how the estimate is constructed and where uncertainty lives.

What is directly verified

• Anca Vlad owns 100% of Fildas Trading SRL, as stated on the official Fildas site and confirmed in business database listings (SeeNews, Trade Register).
• Fildas Trading reported over €1.3 billion in turnover for 2023, per the group's own published figures.
• Smart Soft Power's 2025 net profit of 12.9 million lei was sourced from Romania's Ministry of Public Finance filings, as reported by Ziarul Financiar.
• Forbes Romania ranked Anca Vlad #1 on its 50 Most Powerful Women list in both 2024 and 2025 editions, using CreditSky as a data partner for wealth estimates.
• Capital Romania's Top 300 tracked her fortune across multiple years, showing growth from €84 million to €270-300 million (2017) to €660-700 million in recent editions.
• Historical turnover data: Fildas Trading posted RON 4.2 billion in 2019 per Ziarul Financiar.

What is estimated or assumed

• The net worth figure is derived by applying industry-standard valuation multiples (typically 1x-2x revenue or 8x-12x EBITDA for pharmaceutical distribution businesses) to Fildas Trading's reported revenues, then adjusting for debt and working capital assumptions we cannot independently verify.
• Personal real estate and other private asset values are not publicly disclosed and are not included in the estimate.
• Dividend extraction rates are not publicly known; we assume a significant portion of profits are retained in the business rather than paid out personally.
• The high-end figure of €700 million in the Capital Top 300 may reflect peak-year valuations; we use €650 million as a conservative midpoint.

Academic research on Romanian business rankings, including papers that track tracked fortunes of female entrepreneurs, confirms that estimates like these are typically assembled by aggregating media rankings, business registry data, and revenue-based valuation proxies rather than audited personal balance sheets. That is the honest reality of estimating private wealth in this region.

Wealth timeline: from translator to billionaire-range entrepreneur

Anca Vlad's wealth accumulation follows a clear arc tied directly to Romania's pharmaceutical market liberalization in the post-communist period.

1. Early career: Anca Vlad began her professional life as a translator before transitioning into entrepreneurship, a path detailed in her official biography. The specific founding date of Fildas Trading traces to the early 1990s, when Romania's newly liberalized economy allowed private pharmaceutical distribution for the first time.
2. Early growth phase (1990s-2000s): Fildas grew from a regional distributor into a national player as Romania's pharmaceutical market expanded post-accession. This period established the infrastructure and logistics capability that would underpin later revenue scaling.
3. Mid-tier wealth milestone (~2013-2015): Capital's Top 300 tracked her estimated fortune at approximately €84 million during this period, consistent with a profitable but not yet dominant market position.
4. Acceleration phase (2015-2019): Fildas Trading's 2019 turnover of RON 4.2 billion (up 16% year-on-year) signals the period of fastest absolute growth. By 2017, her estimated fortune had already jumped to €270-300 million per the Capital Top 300.
5. Scale consolidation (2020-2023): The COVID-19 period and its aftermath accelerated pharmacy retail consolidation across Central and Eastern Europe. Fildas-Catena's scale advantages and logistics network made it a clear beneficiary. Turnover crossed €1.3 billion by 2023.
6. Current position (2024-2026): Forbes Romania ranked her #1 among Romania's most powerful women in both 2024 and 2025. Capital Top 300 estimates her fortune at €660-700 million. No major disclosed controversies or income shocks have affected the estimate in this period.

How to verify this number today and what to watch for

If you want to stress-test or update this estimate yourself, here are the most actionable steps and sources to use.

1. Check Romania's Trade Register (ONRC, onrc.ro): Fildas Trading SRL and Catena Pharma SRL are registered Romanian entities. Annual financial statements (bilant) are filed with the Ministry of Public Finance and are accessible via the ONRC portal or listafirme.ro. Look for the most recent turnover (cifra de afaceri), net profit (profit net), and equity (capitaluri proprii) figures.
2. Monitor Capital Romania's Top 300: This is the most credible annual Romanian wealth ranking and the primary source for tracked changes in Anca Vlad's fortune over time. New editions typically publish in the fall each year.
3. Check Forbes Romania: The annual '50 Most Powerful Women' and 'Business Heroes' features use CreditSky financial data and are published with sourcing notes. Forbes Romania's methodology is more transparent than most Eastern European equivalents.
4. Watch Ziarul Financiar (zf.ro): This is Romania's leading financial newspaper and regularly reports on Fildas Trading and Smart Soft Power financial results when Ministry of Public Finance data is released annually.
5. Use SeeNews or Orbis/Bureau van Dijk: For cross-border verification, SeeNews maintains a Fildas Trading SRL company profile that aggregates financial data. Orbis (paid) has deeper balance sheet data if you need it.
6. Interpret wide ranges cautiously: If you see figures ranging from €300 million to €700 million across different sources, that spread is not a sign of unreliable data. It almost always reflects different valuation years, different methodology (revenue multiple vs. EBITDA multiple), and whether or not personal assets beyond the core business are included.

One practical flag to watch: if Fildas Trading or Catena Pharma were ever to pursue a public listing, an IPO prospectus would provide the most reliable single valuation of the group ever published. No such transaction has been announced as of May 2026, but it would be the most significant wealth-verification event possible for this profile.

Controversies affecting the estimate are not prominently documented in the public record as of this writing. No major regulatory sanctions, ownership disputes, or market exits have been reported that would require a downward revision. That said, pharmaceutical distribution margins in Romania have faced pressure from pricing regulation, and any future government intervention in drug pricing or distribution licensing would be the most likely macro factor to affect the group's valuation and, by extension, this estimate.